Altimmune
ALT
36 hedge funds and large institutions have $28.4M invested in Altimmune in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 5 closing their positions.
221% more call options, than puts
Call options by funds: $151K | Put options by funds: $47K
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
8% less funds holding
Funds holding: 39 → 36 (-3)
22% less capital invested
Capital invested by funds: $36.3M → $28.4M (-$7.9M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCI
Jet Capital Investors
New York
|
+$618K |
| 2 |
PCM
Potomac Capital Management
New York
|
+$151K |
| 3 |
Morgan Stanley
New York
|
+$86.3K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$79.1K |
| 5 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$44.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sophrosyne Capital
New York
|
-$335K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$179K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$98.6K |
| 4 |
GMCM
Gruber & McBaine Capital Management
San Francisco,
California
|
-$40.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$40.2K |
ALT Hedge Fund Activity: Q2 2014 in Review
36 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2014, worth a combined $28.4M — down 22% from $36.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ALT and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Jet Capital Investors, adding an estimated $618K. The largest seller was Sophrosyne Capital, exiting entirely with an estimated $335K sold.
- 36 institutional investors held Altimmune (ALT) as of Q2 2014, down from 39 in Q1 2014.
- Funds reported $28.4M of Altimmune stock for Q2 2014, down 22% quarter-over-quarter.
- 2 funds opened new Altimmune positions in Q2 2014 and 5 closed out, a net change of -3 holders.
- The largest Altimmune buyer in Q2 2014 was Jet Capital Investors, an estimated $618K added.
- The largest Altimmune seller in Q2 2014 was Sophrosyne Capital, an estimated $335K sold.
Based on aggregated 13F filings for Q2 2014.